ArticleCase reports in endocrinology2025
Expanding the Phenotypic Spectrum of Differentiated High-Grade Thyroid Carcinoma: An Extracranial Mass as the First Presentation.
Article in Case reports in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiated high-grade thyroid carcinoma (DHGTC) is a recently recognized entity introduced in the 2022 World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors. The prognosis is intermediate between differentiated thyroid carcinoma, which generally has a favorable outcome, and anaplastic thyroid carcinoma, which carries a poor prognosis. Given its recent classification, standardized management guidelines and long-term follow-up data are lacking. Case Presentation: We report a case of a 52-year-old male who presented with a protruding cranial mass with overlying wound dehiscence. Initial pathological analysis of the mass revealed metastatic thyroid carcinoma. Further workup identified a 7 cm × 5 cm mass at the right vertex, invading the right parietal bone and extending into the epidural space. Additionally, a large thyroid mass was observed, causing destruction of the manubrium sternum and upper ribs, with subcutaneous and superior mediastinal extension. The patient underwent cranial mass resection and biopsy of the superior mediastinal mass. Histopathological examination confirmed DHGTC with papillary features and tall cell morphology, involving the dura mater, parietal bone, and scalp. The superior mediastinal biopsy also demonstrated high-grade thyroid carcinoma. The patient had a history of autism spectrum disorder with nonverbal communication. Given the advanced disease stage, the family opted for comfort care. Conclusion: This case highlights the new histopathological criteria for DHGTC and its unusual presentation, emphasizing the challenges in management and prognosis of this newly defined entity. Clinicians should consider DHGTC in atypical extracranial metastatic presentations to facilitate early diagnosis and multidisciplinary management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.